AntigenID™ – CGI’s Neoantigen Discovery Service
Advancing the Development of Personalized and Targeted Immune Therapies
Early last week, we issued a press release formally announcing the launch of our neoantigen discovery service: AntigenID™. This unique and comprehensive offering enables the surveying of existing and discovery of novel neoantigens to accelerate the development of personalized cancer immuno-oncology (IO) therapies while guiding treatment response to existing IO drugs.
Cancer is caused by DNA alterations that ultimately translate into modified proteins in cancer cells that are different from normal cells. These modified proteins, with unique amino acid sequences, are potential sources of neoantigens that potentially expose cancer to our immune system.
Historically, the identification of tumor-specific mutant antigens was a painstaking effort and involved elaborate protocols of molecular cloning and cumbersome screening methods. Now, with new technologies including next generation sequencing (NGS) and sophisticated bioinformatics tools, neoantigen monitoring, profiling and discovery is more routinely attainable. It’s certainly not common – but much more within reach.
These tools enable the predictive selection of novel tumor antigens and unique peptide sequences to estimate binding affinities to the major histocompatibility complex. As a result, individual patient tumors can be surveyed for overall neoantigenic load as a step to personalized immunotherapy response profile generation. Additionally, the manipulation of neoantigens used alone or in combination with other IO drugs could prove to be yet another breakthrough in the IO movement.
There are currently over 50 clinical trials and studies involving neoantigen identification as a core component. Many of them are distinctly geared towards developing personalized vaccines, a prelude to a predicted global cancer immunotherapy market of close to USD 200 Billion by 2021 (from USD 61.97 Billion in 2016). 
CGI’s AntigenID™ utilizes unique and comprehensive sequencing combinations, coupled with proprietary informatics algorithms and computational workflows, to drive neoantigen discovery. It’s based on transcriptomic profiling and somatic/germline genomics analyses – and experiencing rapid uptake by our IO-oriented biopharma clients.
How can CGI’s AntigenID™ power your clinical trial and translational research efforts? This unique offering further expands our comprehensive IO service portfolio, reinforcing CGI as a precision oncology leader and a partner of choice across the biopharma and clinical oncology landscape.
To learn more about this novel profiling service, please send me a note. I’d be happy to schedule time to help evaluate and discuss how this new offering and others on the CGI’s comprehensive IO portfolio could be used to meet your clinical trial and drug development needs.
 MarketsandMarkets. Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) – Global Forecast to 2021.